Literature DB >> 17160613

Restricted upper extremity range of motion in mucopolysaccharidosis type I: no response to one year of enzyme replacement therapy.

J Cox-Brinkman1, M J C Smeulders, C E M Hollak, F A Wijburg.   

Abstract

BACKGROUND: Mucopolysaccharidosis type I (MPS I) results from deficiency of the lysosomal enzyme alpha-L: -iduronidase (IDUA). Glycosaminoglycans (GAGs) accumulate in multiple organs and the storage in connective tissues results in restricted mobility. Previous studies provided evidence of an improvement in range of motion (ROM), as measured by goniometry, after supplementation of recombinant enzyme (ERT). AIM: The aim of the study was to evaluate the efficacy of ERT in improving ROM in patients with MPS I, using a blinded three-dimensional (3D) video analysis of unrestricted movements of the upper extremities.
METHODS: In 6 patients with the attenuated phenotype of MPS I, the longitudinal changes in the upper extremity ROM were analysed by 3D video analysis during one year of ERT.
RESULTS: At baseline, all studied movements except for elbow flexion were restricted. No significant improvement of the restricted upper extremity ROM was observed after one year of ERT.
CONCLUSION: Long-standing restrictions in ROM probably cannot be reversed by ERT. Early initiation of treatment might be essential to prevent irreversible functional defects.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17160613     DOI: 10.1007/s10545-006-0490-x

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  13 in total

1.  Three-dimensional video analysis of forearm rotation before and after combined pronator teres rerouting and flexor carpi ulnaris tendon transfer surgery in patients with cerebral palsy.

Authors:  M Kreulen; M J C Smeulders; H E J Veeger; J J Hage; C M A M van der Horst
Journal:  J Hand Surg Br       Date:  2004-02

2.  Parameters for modeling the upper extremity.

Authors:  H E Veeger; B Yu; K N An; R H Rozendal
Journal:  J Biomech       Date:  1997-06       Impact factor: 2.712

3.  Angular position, range of motion and velocity of arm elevation: a study of consistency of performance.

Authors:  Joan García-Alsina; Concepción García Almazan; José Moranta Mesquida; Eulogio Pleguezuelos Cobo
Journal:  Clin Biomech (Bristol, Avon)       Date:  2005-11       Impact factor: 2.063

Review 4.  Range-of-motion measurements.

Authors:  R D Lea; J J Gerhardt
Journal:  J Bone Joint Surg Am       Date:  1995-05       Impact factor: 5.284

5.  A technique for obtainng spatial kinematic parameters of segments of biomechanical systems from cinematographic data.

Authors:  N R Miller; R Shapiro; T M McLaughlin
Journal:  J Biomech       Date:  1980       Impact factor: 2.712

6.  Two mutations within a feline mucopolysaccharidosis type VI colony cause three different clinical phenotypes.

Authors:  A C Crawley; G Yogalingam; V J Muller; J J Hopwood
Journal:  J Clin Invest       Date:  1998-01-01       Impact factor: 14.808

7.  Enzyme replacement in a canine model of Hurler syndrome.

Authors:  R M Shull; E D Kakkis; M F McEntee; S A Kania; A J Jonas; E F Neufeld
Journal:  Proc Natl Acad Sci U S A       Date:  1994-12-20       Impact factor: 11.205

8.  Intra-articular enzyme administration for joint disease in feline mucopolysaccharidosis VI: enzyme dose and interval.

Authors:  Dyane Auclair; Leanne K Hein; John J Hopwood; Sharon Byers
Journal:  Pediatr Res       Date:  2006-04       Impact factor: 3.756

9.  Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-L-iduronidase (laronidase).

Authors:  James E Wraith; Lorne A Clarke; Michael Beck; Edwin H Kolodny; Gregory M Pastores; Joseph Muenzer; David M Rapoport; Kenneth I Berger; Stuart J Swiedler; Emil D Kakkis; Tanja Braakman; Elenie Chadbourne; Karen Walton-Bowen; Gerald F Cox
Journal:  J Pediatr       Date:  2004-05       Impact factor: 4.406

10.  Shoulder kinematics in subjects with frozen shoulder.

Authors:  Peter J Rundquist; Donald D Anderson; Carlos A Guanche; Paula M Ludewig
Journal:  Arch Phys Med Rehabil       Date:  2003-10       Impact factor: 3.966

View more
  4 in total

1.  Efficacy of recombinant human alpha-L-iduronidase (laronidase) on restricted range of motion of upper extremities in mucopolysaccharidosis type I patients.

Authors:  Anna Tylki-Szymanska; Jolanta Marucha; Agnieszka Jurecka; Malgorzata Syczewska; Barbara Czartoryska
Journal:  J Inherit Metab Dis       Date:  2010-03-09       Impact factor: 4.982

2.  Elevated TNF-α is associated with pain and physical disability in mucopolysaccharidosis types I, II, and VI.

Authors:  Lynda E Polgreen; Richard K Vehe; Kyle Rudser; Alicia Kunin-Batson; Jeanine Jarnes Utz; Patricia Dickson; Elsa Shapiro; Chester B Whitley
Journal:  Mol Genet Metab       Date:  2016-01-28       Impact factor: 4.797

3.  Mechanism of glycosaminoglycan-mediated bone and joint disease: implications for the mucopolysaccharidoses and other connective tissue diseases.

Authors:  Calogera M Simonaro; Marina D'Angelo; Xingxuan He; Efrat Eliyahu; Nataly Shtraizent; Mark E Haskins; Edward H Schuchman
Journal:  Am J Pathol       Date:  2007-12-13       Impact factor: 4.307

Review 4.  Intravenous Enzyme Replacement Therapy in Mucopolysaccharidoses: Clinical Effectiveness and Limitations.

Authors:  Rossella Parini; Federica Deodato
Journal:  Int J Mol Sci       Date:  2020-04-23       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.